Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.2437_138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Interim Analysis of Phase Iiib Magnify Study of Induction R2 Followed by Maintenance in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy